A Phase I, Two-part, Single and Optional Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of 500 and 750 mg PXL770 in Healthy Subjects
Latest Information Update: 05 Jul 2022
At a glance
- Drugs PXL 770 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Poxel
Most Recent Events
- 05 Jul 2022 New trial record